Comparative analysis of clinical and imaging data between patients with myelin oligodendrocyte glycoprotein antibody disease and patients with aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder

Xie, Haojie; Shao, Yingzhe; Du, Juan; Song, Yajun; Li, Yanfei; Duan, Ranran; Yao, Yaobing; Gong, Zhe; Teng, Junfang; Jia, Yanjie

doi:10.1007/s00415-021-10749-6

Cited by 3 publications

(4 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nonspecific leptomeningeal around the brainstem; cortical (linear) enhancement (with cerebral cortical encephalitis) 3 has also been described. A higher frequency of deep gray matter involvement in MOGAD versus AQP4‐ab‐positive NMOSD has been reported 74,75 …”

Section: Brain Mrimentioning

confidence: 93%

“…A higher frequency of deep gray matter involvement in MOGAD versus AQP4-ab-positive NMOSD has been reported. 74,75 Importantly, during follow-up, the resolution of T2 brain lesions is most common in MOGAD compared with AQP4-ab-positive NMOSD and MS, being another important feature to differentiate the three conditions. 30,76 Ovoid periventricular "Dawson fingers" lesions are rarely seen in MOGAD, while extra callosal extension (55%) and T2 MRI lesion resolution (56%) were most common in MOGAD when compared with NMOSD and MS. 56 Brainstem lesions are found in up to 40% of MOGAD patients, 65,77 often affecting the pons, medulla oblongata, and middle cerebellar peduncles (generally adjacent to the fourth ventricle).…”

Section: Brain Lesions Characteristic Of Mogadmentioning

confidence: 99%

See 1 more Smart Citation

MRI to differentiate multiple sclerosis, neuromyelitis optica, and myelin oligodendrocyte glycoprotein antibody disease

Contentti

Okuda

Rojas³

et al. 2023

Journal of Neuroimaging

View full text Add to dashboard Cite

Differentiating multiple sclerosis (MS) from other relapsing inflammatory autoimmune diseases of the central nervous system such as neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) is crucial in clinical practice. The differential diagnosis may be challenging but making the correct ultimate diagnosis is critical, since prognosis and treatments differ, and inappropriate therapy may promote disability. In the last two decades, significant advances have been made in MS, NMOSD, and MOGAD including new diagnostic criteria with better characterization of typical clinical symptoms and suggestive imaging (magnetic resonance imaging [MRI]) lesions. MRI is invaluable in making the ultimate diagnosis. An increasing amount of new evidence with respect to the specificity of observed lesions as well as the associated dynamic changes in the acute and follow‐up phase in each condition has been reported in distinct studies recently published. Additionally, differences in brain (including the optic nerve) and spinal cord lesion patterns between MS, aquaporin4‐antibody‐positive NMOSD, and MOGAD have been described. We therefore present a narrative review on the most relevant findings in brain, spinal cord, and optic nerve lesions on conventional MRI for distinguishing adult patients with MS from NMOSD and MOGAD in clinical practice. In this context, cortical and central vein sign lesions, brain and spinal cord lesions characteristic of MS, NMOSD, and MOGAD, optic nerve involvement, role of MRI at follow‐up, and new proposed diagnostic criteria to differentiate MS from NMOSD and MOGAD were discussed.

show abstract

Section: Brain Mrimentioning

confidence: 93%

Section: Brain Lesions Characteristic Of Mogadmentioning

confidence: 99%

MRI to differentiate multiple sclerosis, neuromyelitis optica, and myelin oligodendrocyte glycoprotein antibody disease

Contentti

Okuda

Rojas³

et al. 2023

Journal of Neuroimaging

View full text Add to dashboard Cite

show abstract

“…In contrast, another study found that serum uric acid levels in NMOSD patients during relapses were significantly lower than those in healthy individuals and that these reduced uric acid levels during NMOSD relapse were normalized during remission ( 66 ). In addition, in the differentiation of myelin oligodendrocyte glycoprotein antibody disease and NMOSD, serum uric acid is higher in myelin oligodendrocyte glycoprotein antibody disease, suggesting that serum uric acid may be a potential marker to differentiate these two diseases ( 67 ). Liu et al reported that serum uric acid levels were correlated with NMOSD disease duration and inversely correlated with disability scores, suggesting that serum uric acid may be a useful biomarker for monitoring disease activity ( 68 ).…”

Section: Neuromyelitis Optica Spectrum Disordermentioning

confidence: 99%

Uric acid and neurological disease: a narrative review

et al. 2023

View full text Add to dashboard Cite

Hyperuricemia often accompanies hypertension, diabetes, dyslipidemia, metabolic syndrome, and chronic renal disease; it is also closely related to cardiovascular disease. Moreover, several epidemiological studies have linked hyperuricemia and ischemic stroke. However, uric acid may also have neuroprotective effects because of its antioxidant properties. An association between low uric acid levels and neurodegenerative diseases has been suggested, which may be attributed to diminished neuroprotective effects as a result of reduced uric acid. This review will focus on the relationship between uric acid and various neurological diseases including stroke, neuroimmune diseases, and neurodegenerative diseases. When considering both the risk and pathogenesis of neurological diseases, it is important to consider the conflicting dual nature of uric acid as both a vascular risk factor and a neuroprotective factor. This dual nature of uric acid is important because it may help to elucidate the biological role of uric acid in various neurological diseases and provide new insights into the etiology and treatment of these diseases.

show abstract

“…Myelin oligodendrocyte glycoprotein antibody-related disease (MOGAD) is a kind of autoimmune disease recently found ( Dubey et al, 2019 ; Xie et al, 2022 ). The pathological manifestation of MOGAD is the demyelination of the CNS.…”

Section: Neurologic Autoimmune Disorders and Glial Cellsmentioning

confidence: 99%

Glial cells and neurologic autoimmune disorders

Li²,

Tian³

et al. 2022

Front. Cell. Neurosci.

View full text Add to dashboard Cite

Neurologic autoimmune disorders affect people’s physical and mental health seriously. Glial cells, as an important part of the nervous system, play a vital role in the occurrence of neurologic autoimmune disorders. Glial cells can be hyperactivated in the presence of autoantibodies or pathological changes, to influence neurologic autoimmune disorders. This review is mainly focused on the roles of glial cells in neurologic autoimmune disorders and the influence of autoantibodies produced by autoimmune disorders on glial cells. We speculate that the possibility of glial cells might be a novel way for the investigation and therapy of neurologic autoimmune disorders.

show abstract

Comparative analysis of clinical and imaging data between patients with myelin oligodendrocyte glycoprotein antibody disease and patients with aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder

Cited by 3 publications

References 45 publications

MRI to differentiate multiple sclerosis, neuromyelitis optica, and myelin oligodendrocyte glycoprotein antibody disease

MRI to differentiate multiple sclerosis, neuromyelitis optica, and myelin oligodendrocyte glycoprotein antibody disease

Uric acid and neurological disease: a narrative review

Glial cells and neurologic autoimmune disorders

Contact Info

Product

Resources

About